Impact of fixed-dose combination of isosorbide dinitrate and hydralazine on heart failure progression in an African American population: Focus on mode of death and hospitalization

被引：0

作者：

Carson, Peter

Anand, Inder

Ghali, Jalal K.

Lindenfeld, JoAnn

Miller, Alan B.

Tristani, Felix

Braman, Virginia M.

Worcel, Manuel

Sabolinski, Michael L.

机构：

[1] Vet Affairs Med Ctr, Washington, DC 20422 USA

[2] Vet Affairs Med Ctr, Minneapolis, MN USA

[3] Wayne State Univ, Detroit, MI USA

[4] Univ Colorado, Denver, CO 80202 USA

[5] Univ Florida, Jacksonville, FL USA

[6] NitroMed Inc, Lexington, MA USA

来源：

CIRCULATION | 2006年 / 114卷 / 18期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：572 / 572

页数：1

共 47 条

[21] Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure
Echols, Melvin R.
Yancy, Clyde W.
VASCULAR HEALTH AND RISK MANAGEMENT, 2006, 2 (04) : 423 - 431
[22] Fixed-dose combination of isosorbide dinitrate and hydralazine inhibits left ventricular remodeling in well-treated severe heart failure in African-Americans: A-HeFT
Cohn, JN
Anand, I
Taylor, A
Tan, SW
CIRCULATION, 2005, 112 (17) : U704 - U704
[23] Fixed-dose combination of isosorbide dinitrate and hydralazine inhibits left ventricular remodeling in well-treated severe heart failure in African-Americans: A-HeFT
Cohn, JN
Anand, I
Taylor, A
JOURNAL OF CARDIAC FAILURE, 2005, 11 (09) : 720 - 720
[24] The benefits of the fixed-dose combination of isosorbide dinitrate and hydralazine in A-HeFT are not influenced by the absence or presence of diabetes
Miller, Alan
Yancy, Clyde W.
Sabofinski, Michael L.
Braman, Virginia M.
Worcel, Manuel
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (09) : 44A - 44A
[25] Lack of Bioequivalence between Different Formulations of Isosorbide Dinitrate and Hydralazine and the Fixed-Dose Combination of Isosorbide Dinitrate/HydralazineThe V-HeFT Paradox
S. William Tam
Michael L. Sabolinski
Manuel Worcel
Milton Packer
Jay N. Cohn
Clinical Pharmacokinetics, 2007, 46 : 885 - 895
[26] GNB3 TT genotype predicts enhanced benefit of fixed-dose combination of isosorbide dinitrate and hydralazine in African Americans with heart failure: Results of the A-HeFT trial
McNamara, Dennis M.
Tam, S. William
Sabolinski, Michael L.
Tobelmann, Page
Hanley-Yanez, Karen
Janosko, Karen M.
Worcel, Manuel
JOURNAL OF CARDIAC FAILURE, 2006, 12 (06) : S71 - S71
[27] Effect of angiotensin converting enzyme inhibitor or beta-blocker use on the benefit of fixed-dose combined isosorbide dinitrate/hydralazine in the African-American heart failure trial
Ghali, Jalal K.
Taylor, Anne L.
Tam, S. William
Sabolinski, Michael L.
Worcel, Manuel
Cohn, Jay N.
JOURNAL OF CARDIAC FAILURE, 2006, 12 (06) : S80 - S80
[28] Effects of Fixed-Dose Isosorbide Dinitrate/Hydralazine on Diastolic Function and Exercise Capacity in Hypertension-Induced Diastolic Heart Failure
Wilson, Richard M.
De Silva, Deepa S.
Sato, Kaori
Izumiya, Yasuhiro
Sam, Flora
HYPERTENSION, 2009, 54 (03) : 583 - U265
[29] In-trial economic evaluation of a fixed-dose combination of isosorbide dinitirate and hydralazine in blacks with heart failure: Results from the African-American Heart Failure Trial (A-HeFT)
Linde-Zwirble, WT
Tam, SW
Worcel, M
Sabolinski, ML
Ghali, J
Angus, DC
JOURNAL OF CARDIAC FAILURE, 2005, 11 (06) : S151 - S151
[30] Clinical Effectiveness of Hydralazine-Isosorbide Dinitrate in African-American Patients With Heart Failure
Ziaeian, Boback
Fonarow, Gregg C.
Heidenreich, Paul A.
JACC-HEART FAILURE, 2017, 5 (09) : 632 - 639

← 1 2 3 4 5 →